Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    Goodbye Privacy: Big Data Is Coming to Town

    If the Edward Snowden case has you worried about what the government knows about you, you should see what your favorite retailer, web portal or email service has on you. It's even more shocking. But big data isn't going away. It's going to get bigger. It’s going to reach further into our lives. Check out how to invest in this growing business. Oh wait, somebody already knows you are...
    Read More...
  • Invest in Big Data